IGLV1-36: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: IGLV1-36

NCBI ID: G28826

IGLV1-36

Other Name(s): V1-11 | Immunoglobulin lambda variable 1-36 | IGLV136 | immunoglobulin lambda variable 1-36

IGLV1-36: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), and chronic obstructive pulmonary disease (COPD), are characterized by chronic inflammation and damage to various neural tissues. These conditions can cause significant morbidity and economic burden, particularly in the form of lost productivity and increased healthcare costs. The development of new, effective treatments for these diseases remains a major goal in the field of neuroscience.

IGLV1-36: A Potential Drug Target and Biomarker

IGLV1-36 is a highly conserved non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its function and regulation in these diseases are still being explored, but its potential implications are significant.

IGLV1-36 as a Drug Target:

The search for new treatments for inflammatory neurodegenerative diseases has led to the development of various small molecules and biologics that target various components of the immune system. These treatments often have limited efficacy and can cause adverse side effects. IGLV1-36, however, differs from other drug targets in that it is a non-coding RNA molecule that has been shown to play a critical role in the regulation of immune responses and inflammation.

IGLV1-36 has been shown to regulate the activity of various immune cells, including T cells, B cells, and natural killer cells. It has also been shown to play a role in modulating the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12. These cytokines are central to the development and progression of inflammatory neurodegenerative diseases. By targeting IGLV1-36, researchers may be able to develop new treatments that specifically target the underlying causes of these diseases.

IGLV1-36 as a Biomarker:

IGLV1-36 may also serve as a biomarker for the diagnosis and monitoring of inflammatory neurodegenerative diseases. The development of biomarkers for these diseases has the potential to improve disease diagnosis, treatment outcomes, and patient management. IGLV1-36 has been shown to be expressed in various tissues and cells associated with the development of inflammatory neurodegenerative diseases, including brain, spleen, and peripheral tissues.

IGLV1-36 has also been shown to be regulated by various factors, including cytokines, chemokines, and DNA methylation. These factors may play a role in the regulation of IGLV1-36 expression and its function in the immune system. By studying the regulation of IGLV1-36, researchers may be able to identify new targets for the development of biomarkers and potential treatments for inflammatory neurodegenerative diseases.

Conclusion

In conclusion, IGLV1-36 is a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its unique function and regulation in these diseases make it an attractive target for new treatments. Further research is needed to fully understand the role of IGLV1-36 in the development and progression of inflammatory neurodegenerative diseases, as well as its potential as a biomarker for the diagnosis and monitoring of these conditions.

Protein Name: Immunoglobulin Lambda Variable 1-36

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV1-36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV1-36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets